Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intron

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Intron. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-002275-40 Sponsor Protocol Number: 2006-002275-40 Start Date*: 2007-01-24
    Sponsor Name:Uppsala University Hospital, Dept. of Medical Sciences
    Full Title: Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids
    Medical condition: Metastasizing ileal/coecal carcinoids (WHO ICD-10 code: C17.9)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003814-14 Sponsor Protocol Number: ML19498 Start Date*: 2006-03-13
    Sponsor Name:Unidad Integral de Investigación en Oncología, S.L.
    Full Title: Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Medical condition: Mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011182-86 Sponsor Protocol Number: BLX883-204 Start Date*: 2009-07-24
    Sponsor Name:Biolex Therapeutics, Inc
    Full Title: 480 Study: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects with HCV Genotype 1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron™ Plus Ribavirin ...
    Medical condition: Approximately 72 subjects with chronic hepatitis C (treatment naive, genotype 1) will be included in a 12 week open label randomized trial with 2 panels (approximately 40 subjects in PANEL A and ap...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007649-30 Sponsor Protocol Number: BLX883-203 Start Date*: 2009-06-25
    Sponsor Name:Biolex Therapeutics Inc.
    Full Title: SELECT-2: Phase 2B, Partially Blinded, Randomized Study In Treatment Naïve Subjects With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three Doses of Locteron™ Plus Ribavirin ...
    Medical condition: Approximately 100 treatment-naïve adults with chronic hepatitis C genotype 1, who meet eligibility criteria, will be enrolled at approximately 35 study sites in Europe and the United States (U.S.).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023124-24 Sponsor Protocol Number: LUMCCHIP Start Date*: 2011-03-02
    Sponsor Name:Academisch Ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum
    Full Title: Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. ...
    Medical condition: Recurrent platinum resistant, p53 positive ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000820-34 Sponsor Protocol Number: P03548 Start Date*: 2006-08-31
    Sponsor Name:Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough
    Full Title: Comparison of Three Regimens of PEG-Intron plus Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients
    Medical condition: Chronic Hepatitis C, Genotype 2 or 3
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003160-19 Sponsor Protocol Number: ASL608LIOM01 Start Date*: 2008-09-07
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETR...
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001167 Adenocarcinoma of colon LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001426-24 Sponsor Protocol Number: P02470 Start Date*: 2004-11-23
    Sponsor Name:Prof. Heinz Ludwig, MD, Wilhelminenspital, First Department of Medicine and Medical Oncology
    Full Title: Multicenter, open, randomized study for first-line treatment of multiple myeloma: thalidomide/dexamethasone vs. MP for induction therapy and thalidomide/Intron A vs. Intron A for maintenance therapy
    Medical condition: First line treatment of multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-000757-21 Sponsor Protocol Number: P04823 Start Date*: 2006-08-15
    Sponsor Name:AESCA Pharma GmbH
    Full Title: Study to evaluate Response Rates in CHC Patients genotype 1 with Insulin Resistance and to assess prolonged Treatment Duration in late virological Responders
    Medical condition: chronic hepatitis C, genotype 1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001264-31 Sponsor Protocol Number: P03659 Start Date*: 2005-07-06
    Sponsor Name:SCHERING-PLOUGH
    Full Title: Peg-Intron/Rebetol vs Peg-Intron / SCH 503034 with and without Ribavirin in Chronic Hepatitis C HCV 1 Peginterferon alfa/Ribavirin Nonresponders: A SCH 503034 dose finding Phase 2 Study.
    Medical condition: Adult patients with Chronic hepatitis C HCV-1 without cirrhosis nonresponders to a previous standard treatment of 12 weeks.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10019744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000558-22 Sponsor Protocol Number: P02538 Start Date*: 2005-06-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Assessment of the safety, efficacy, tolerability and pharmacokinetics of PegIntron plus Rebetol in pediatric patients with chronic hepatitis C.
    Medical condition: Chronic Hepatitis C in pediatric patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-005166-20 Sponsor Protocol Number: 04.10 Start Date*: 2005-04-14
    Sponsor Name:Odense University Hospital
    Full Title: Phase II study of first-line therapy with Thalidomide in combination with Peg-introna and decrescendo IL-2 in patients with metastatic malignant melanoma
    Medical condition: Metastatic malignant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-005545-20 Sponsor Protocol Number: IJBNMDOCASTOR Start Date*: 2014-12-23
    Sponsor Name:Institut Jules Bordet
    Full Title: The CaStOR study Carcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b
    Medical condition: Progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine tumors resistant to therapy with somatostatin analogues.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003876-39 Sponsor Protocol Number: P04371 Start Date*: 2006-09-19
    Sponsor Name:Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough
    Full Title: A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patient...
    Medical condition: Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus
    Disease: Version SOC Term Classification Code Term Level
    9.0 10019641 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004981-16 Sponsor Protocol Number: 1991-201-008 Start Date*: 2022-06-17
    Sponsor Name:Editas Medicine, Inc.
    Full Title: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Cen...
    Medical condition: Leber Congenital Amaurosis Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in I...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10015920 Eye disorders congenital HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001220-20 Sponsor Protocol Number: P03833 Start Date*: 2005-01-25
    Sponsor Name:Integrated Therapeutics Group, Incorporated - a subsidiary of Schering-Plough
    Full Title: Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys
    Medical condition: Chronic Hepatitis C, Genotype 1
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000925-38 Sponsor Protocol Number: UCL13/0076 Start Date*: 2017-01-04
    Sponsor Name:University College London (UCL)
    Full Title: GO-8: Gene therapy for haemophilia A using a novel serotype 8 capsid pseudotyped adeno-associated viral vector encoding Factor VIII-V3
    Medical condition: Severe Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-008342-20 Sponsor Protocol Number: RAA08-015 Start Date*: 2009-02-23
    Sponsor Name:King's College London
    Full Title: Genetically determined brain abnormalities in Down’s Syndrome.- towards a treatment: A randomised, single-blind, placebo-controlled trial of lithium carbonate in Down’s Syndrome (DownsLit).
    Medical condition: Down's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10013616 Down's syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005576-22 Sponsor Protocol Number: 201501 Start Date*: 2018-05-22
    Sponsor Name:BAXALTA INNOVATIONS GMBH
    Full Title: A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVII...
    Medical condition: Hemophilia A is a rare congenital disease characterized by reduced or absent levels of the coagulation FVIII. It occurs in approximately 1 in 5,000 live male births. Mutations of the FVIII gene res...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000410-18 Sponsor Protocol Number: 061002 Start Date*: 2011-05-05
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A PHASE 3b CLINICAL STUDY TO ASSESS WHETHER REGULAR ADMINISTRATION OF ADVATE IN THE ABSENCE OF IMMUNOLOGICAL DANGER SIGNALS REDUCES THE INCIDENCE RATE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS...
    Medical condition: Prevention of inhibitor formation, and immune tolerance induction in patients with severe and moderately severe hemophilia A by early and low-dose prophylactic ADVATE therapy
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male
    Trial protocol: AT (Prematurely Ended) DE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) BG (Completed) ES (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) PL (Prematurely Ended) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 20:02:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA